Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.3050 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Adaptimmune's Cancer Candidate Shows 44% Response Rate In Pretreated Ovarian, Urothelial, Head & Neck Cancers
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
- 44% Objective Response Rate (ORR) with a single dose of ADP-A2M4CD8 in 25 heavily pre-treated patients with late-stage ovarian,... 
Via Newsfile
Adaptimmune to Host Live, Virtual Event to Review Phase 1 SURPASS Trial Data and Outline Plans for Further Development in SURPASS Family of Trials
- Event to be held on Friday, September 9th, at 8 a.m. EDT -Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp.... 
Via Newsfile
Adaptimmune Therapeutics: Q2 Earnings Insights
  Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Adaptimmune Reports Second-Quarter Financial Results and Business Update
- Reaffirming financial guidance; Company funded into early 2024 -- ASCO data confirms afami-cel potential for synovial sarcoma; BLA submission... 
Via Newsfile
Adaptimmune to Report Q2 2022 Financial Results and Business Updates on Thursday, August 4, 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - July 21, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in... 
Via Newsfile
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Adaptimmune Therapeutics's Return On Capital Employed Insights
Benzinga Pro data, Adaptimmune Therapeutics (NASDAQ:ADAP) reported Q1 sales of $3.58 million. Earnings fell to a loss of $50.27 million, resulting in a 29.36% decrease from last quarter. 
Via Benzinga
Clinical Responses Reported across Patient Subgroups with Adaptimmune's Cell Therapy, Afami-cel, Confirming Potential for People with Rare Sarcomas - BLA Submission On-Track
- Patients who responded to afami-cel had longer progression-free survival (median 58 weeks) compared to non-responders (median 12 weeks) --... 
Via Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Adaptimmune Therapeutics (NASDAQ:ADAP) stock rose 12.7% to $1.6 during Monday's after-market session. The market value of their outstanding shares is at $258.9 million. 
Via Benzinga
Adaptimmune Therapeutics: Q1 Earnings Insights
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q1 earnings results on Monday, May 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Adaptimmune Therapeutics Q1 2022 Earnings Conference Call On May 9, 2022 At 08:00 AM ET
Adaptimmune Therapeutics (NASDAQ:ADAP) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Looking Into Adaptimmune Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q4, Adaptimmune Therapeutics (NASDAQ:ADAP) posted sales of $1.42 million. Earnings were up 8.36%, but Adaptimmune Therapeutics still... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Incannex Healthcare (NASDAQ:IXHL) stock moved upwards by 92.3% to $44.04 during Tuesday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
Adaptimmune Therapeutics: Q4 Earnings Insights
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q4 earnings results on Monday, March 14, 2022 at 07:30 AM. Here's what investors need to know about the announcement... 
Via Benzinga
A Preview Of Adaptimmune Therapeutics's Earnings
Adaptimmune Therapeutics (NASDAQ:ADAP) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.... 
Via Benzinga
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell • F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter. • The One Group Hospitality (... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Mustang Bio (NASDAQ:MBIO) shares ... 
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
Why Adaptimmune Therapeutics Stock Is Crashing Today
Investor sentiment has turned against this promising cell therapy company. 
Via The Motley Fool
Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial
Adaptimmune Therapeutics plc (NASDAQ: ADAP) will report updated data from its SPEARHEAD-1 Phase 2 trial with afamitresgene autoleucel (afami-cel, ADP-A2M4) in... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Transcript
ADAP earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Adaptimmune Therapeutics: Q3 Earnings Insights
Adaptimmune Therapeutics (NASDAQ:ADAP) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.